Sotorasib

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 627 publications

Sotorasib and Panitumumab: A breakthrough in the treatment of KRAS-mutated mCRC.

Sotorasib and Panitumumab: A breakthrough in the treatment of KRAS-mutated mCRC.

Journal: JPMA. The Journal of the Pakistan Medical Association
Published: September 07, 2026

Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions

Therapeutic Strategies Targeting the KRAS G12C Mutation-Current Landscape and Future Directions

Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: August 04, 2026

Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)

Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)

Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: August 04, 2026

Targeting KRAS-Mutant Cancers-Therapeutic Strategies and Mechanisms of Resistance to RAS Inhibitors

Targeting KRAS-Mutant Cancers-Therapeutic Strategies and Mechanisms of Resistance to RAS Inhibitors

Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: August 04, 2026

Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.

Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.

Journal: Journal of medicinal chemistry
Published: July 14, 2026

KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies.

KRAS mutations as architects of the tumor immune microenvironment: implications for combination therapies.

Journal: Frontiers in oncology
Published: July 10, 2026

Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in vitro and in a mouse tumor xenograft.

Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in vitro and in a mouse tumor xenograft.

Journal: Neoplasia (New York, N.Y.)
Published: July 10, 2026

M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLS.

M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLS.

Journal: bioRxiv : the preprint server for biology
Published: July 08, 2026

Targeting KRASG12C in non-small cell lung cancer: evidence from randomized clinical trials and future therapeutic strategies.

Targeting KRASG12C in non-small cell lung cancer: evidence from randomized clinical trials and future therapeutic strategies.

Journal: Frontiers in oncology
Published: June 22, 2026

Development of a PK/PD-Efficacy Modeling Framework for Covalent Inhibitors.

Development of a PK/PD-Efficacy Modeling Framework for Covalent Inhibitors.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: June 12, 2026

Durable Response to Sotorasib Plus Panitumumab in NRAS G12C-Mutated, Microsatellite Instability-High (MSI-H) Rectal Cancer Refractory to Immunotherapy.

Durable Response to Sotorasib Plus Panitumumab in NRAS G12C-Mutated, Microsatellite Instability-High (MSI-H) Rectal Cancer Refractory to Immunotherapy.

Journal: Cureus
Published: June 04, 2026

Standard Versus Reduced Sotorasib Dosing in KRAS G12C-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis-Have We Answered the Dosing Question?

Standard Versus Reduced Sotorasib Dosing in KRAS G12C-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis-Have We Answered the Dosing Question?

Journal: JCO oncology practice
Published: June 01, 2026
Showing 1-12 of 627

Last Updated: 09/26/2026